Please use this identifier to cite or link to this item:
Title: Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.
Austin Authors: Forsyth, Cecily J;Chan, Wai-Hoong;Grigg, Andrew P ;Cook, Nathalie C;Lane, Steven W;Burbury, Kate L;Perkins, Andrew C;Ross, David M
Affiliation: Department of Medicine, Wyong Hospital Wyong, NSW
Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Nutrition and Dietetics, Banyule Community Health, Melbourne, VIC
MPN Alliance, Australia
Department of Haematology, Royal Brisbane and Women's Hospital, and Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD
School of Medicine, University of Queensland, Brisbane, QLD
Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC
Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC
Department of Haematology, Royal Adelaide Hospital and Flinders Medical Centre, and Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA
Issue Date: 2019 2018-11-08
Publication information: Internal Medicine Journal 2019; 49(8): 948-954
Abstract: The classical myeloproliferative neoplasms (MPN) are uncommon clonal haematopoietic malignancies characterised by excessive production of mature blood cells. Clinically they are associated with thrombosis, haemorrhage, varying degrees of constitutional disturbance, and a risk of progression to myelofibrosis or acute myeloid leukaemia. Many of the disease manifestations may be ameliorated by treatment with interferon-α (IFN) but its use in Australian MPN patients has been limited due to the inconvenience of frequent injections and side effects. The pegylated form of IFN is a long-acting preparation which is better tolerated and its Pharmaceutical Benefits Scheme listing is likely to lead to increased usage. We review the literature on risks and benefits of IFN treatment for MPNs, suggest criteria for patient selection in each of these diseases, and discuss strategies to manage the side effects of pegylated IFN. This article is protected by copyright. All rights reserved.
DOI: 10.1111/imj.14154
ORCID: 0000-0002-9108-3088
Journal: Internal Medicine Journal
PubMed URL: 30411442
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.